HONG KONG – After the kickback scandal involving Novartis AG, South Korean authorities are determined to root out corruption from the country's pharmaceutical sector.
HONG KONG – Tokyo-based Peptidream Inc. is partnering with New Haven, Conn.-based Kleo Pharmaceuticals Inc. to develop immuno-oncology (IO) products in multiple indications.
HONG KONG – After the kickback scandal involving Novartis AG, South Korean authorities are determined to root out corruption from the country's pharmaceutical sector. (See BioWorld Today, Sept. 6, 2016.)
HONG KONG – After more than a decade of development, Tissuegene Inc. and its Asia licensee, Kolon Life Science Inc., received approval from South Korean regulatory authorities to market Invossa-K, a gene therapy for degenerative arthritis.
HONG KONG – Tokyo-based Peptidream Inc. is partnering with New Haven, Conn.-based Kleo Pharmaceuticals Inc. to develop immuno-oncology (IO) products in multiple indications.
HONG KONG – After more than a decade of development, Maryland-based Tissuegene Inc. and its Asia licensee, Kolon Life Science Inc., received a bittersweet go-ahead from the South Korean authorities to market gene therapy drug Invossa-K.
HONG KONG – After more than a decade of development, Maryland-based Tissuegene Inc. and its Asia licensee, Kolon Life Science Inc., received a bittersweet go-ahead from the South Korean authorities to market gene therapy drug Invossa-K.
HONG KONG – Facing increased U.S. regulatory scrutiny, India's largest drugmaker, Sun Pharmaceutical Industries Ltd., is outsourcing some of its manufacturing in a deal that provides South Korea's Samsung Biologics Co. Ltd., the biologics manufacturing arm of the Samsung conglomerate, an opportunity to expand its market share.
